The announcement comes as G.E.’s chief executive, Jeffrey Immelt, tries to fix the troubled conglomerate, which has been hit hard by the slumping economy.
The announcement comes as G.E. amp x2019 s chief executive, Jeffrey Immelt, tries to fix the troubled conglomerate, which has been hit hard by the slumping economy.
ImClone Systems Incorporated (NASDAQ: IMCL), a global leader in the development and commercialization of novel antibodies to treat cancer, today announced that significant scientific data on ERBITUX(R) (cetuximab) will be presented at the American Society of Clinical Oncology (ASCO) 2008 Annual Meeting taking place May 30 through June 3, 2008 in Chicago. In total, ImClone and its partners
New Jersey's Democratic delegation literally stood in solidarity with Sen. Frank R. Lautenberg at a Washington press conference Thursday. The incumbent is facing a strong primary challenge from the only Democratic state member who was not in attendance: nine-term Rep. Robert E. Andrews.
ImClone Systems Incorporated (NASDAQ: IMCL) today announced data from the Phase II OPUS study that show that the addition of ERBITUX(R) (cetuximab) to FOLFOX chemotherapy significantly improves both response rate and progression-free survival over FOLFOX alone in the first-line treatment of metastatic colorectal cancer (mCRC) patients whose tumors do not have mutations of the K-Ras oncogene
James D. Coates, 49; Madalyn O. Helm, 85; Catherine G. Crider, 84; Ruth E. Decker, 82; Ralph E. Pine, 82; Kenneth G. Eccleston, 73; Ella E. Hutzler, 78; Gladys M. Beard, 91; Wanda M. Smith, 88
Wasps: J Lewsey; P Sackey, F Waters, R Flutey, T Voyce; D Cipriani, E Reddan; T Payne, R Ibanez, P Barnard, S Shaw, T Palmer, J Haskell, T Rees, L Dallaglio (capt).
Sanofi-aventis (Paris:SAN)(NYSE:SNY) announced today that findings from the landmark ATHENA study showed that Multaq(R) (dronedarone), a potential therapy for the treatment of patients with atrial fibrillation or atrial flutter, decreased the risk of cardiovascular hospitalisations or death from any cause by a statistically significant 24% (p=0.00000002), meeting the study's primary endpoint.
Paris (ots/PRNewswire) - Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that findings from the landmark ATHENA study showed that Multaq(R) (dronedarone), a potential therapy for the treatment of patients with atrial fibrillation or atrial flutter, decreased the risk of cardiovascular hospitalisations or death from any cause by a statistically significant 24% (p=0.00000002), meeting
Paris (ots/PRNewswire) - Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that findings from the landmark ATHENA study showed that Multaq(R)
View comments
Hide comments